|
|
Article: Amarin Appoints Medpace as CRO for Two Phase 3 Cardiovascular Trials.
- Article from:
- Clinical Trials Week
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amarin Corporation plc (NASDAQ:AMRN) announced that it has executed an agreement with Medpace, Inc. ('Medpace'), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia (see also Amarin Corporation plc).
Dr. Doogan, Interim Chief Executive Officer of Amarin, commented "Following extensive due diligence on several global CROs, we selected Medpace based on their expertise in conducting cardiovascular and ...